Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 masitinib plus riluzole versus placebo plus riluzole in amyotrophic lateral sclerosis
MOH_2020-12-07_008659Phase 3Not yet recruiting
- Sponsor
- AB Science
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of masitinib in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by AB Science. Primary endpoint: Change in ALSFRS-R decline from baseline after 48 weeks. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
masitinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on MOH_2020-12-07_008659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-07_008659.